Capricorn Fund Managers Ltd has filed its latest 13F-HR report, revealing a total of $1.06 billion in assets under management as of September 30, 2026. This filing is significant as it provides insights into the company's investment strategies and portfolio adjustments during the quarter.
The report indicates a diverse range of holdings across various sectors, which may influence market trends and investor sentiment in the asset management industry. Notably, competitors such as Blackrock and Apollo Global Management are also active in similar investment strategies, making Capricorn's updates particularly relevant in the context of industry competition.
Background
Capricorn Fund Managers Ltd is an asset management firm that specializes in managing investment portfolios for a variety of clients. The company is registered under the Central Index Key (CIK) 0001901361. Its recent filings indicate a focus on maintaining a diverse portfolio to optimize returns for its investors.
What the Filing Says
The 13F-HR filing, dated November 3, 2026, shows that Capricorn Fund Managers has a total of 138 entries in its portfolio, with a total value of $1,059,437,000. This reflects the company's ongoing commitment to transparency and regulatory compliance.
Impact
This filing may affect various stakeholders, including investors, analysts, and competitors. Investors may gain insights into Capricorn's investment strategies, while analysts can assess the firm's market positioning relative to its competitors. Additionally, the diverse portfolio may influence market trends, prompting other firms to adjust their strategies accordingly.
What's Next
The filing does not say what happens next.
Read Next
Lavelle Capital LP Reports Major Tech Holdings in 13F Filing
HUB Investment Partners reveals latest investment holdings
XPONANCE LLC Reports $17 Billion in Holdings as of Q3 2026
Veratis Advisors reports $132M in holdings as of Sept 2026
Willis Johnson Wealth reports significant tech investments
Curative Ventures V LLC reports holdings in Instil Bio, Inc.








